FDA Grants RMAT Designation to RZ-001 in Advanced Hepatocellular Carcinoma
RZ-001 has received FDA Regenerative Medicine Advanced Therapy (RMAT) designation for the treatment of hepatocellular carcinoma (HCC).
The FDA has granted Regenerative Medicine Advanced Therapy (RMAT) designation to RZ-001, a first‑in‑class RNA trans‑splicing ribozyme gene therapy, for the management of hepatocellular carcinoma. RZ‑001 selectively targets hTERT‑expressing cancer cells, replacing tumor‑specific hTERT RNA with a therapeutic transgene to induce apoptosis, and has shown preliminary clinical activity in an ongoing phase 1b/2a trial (NCT06695026).
The RMAT designation validates RZ‑001 as a promising breakthrough therapy in HCC—a disease with high unmet medical need and limited treatment options. It supports accelerated development and potentially faster access to a novel, gene‑based intervention for patients with advanced hepatocellular carcinoma.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Quercetin suppresses the progression of HBV-associated hepatocellular carcinoma by modulating the EGFR signaling pathway
- Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
- Surgical treatment of hepatocellular carcinoma: expert consensus statement
- Loco-regional treatment of hepatocellular carcinoma
- Real‑World Outcomes of Atezolizumab‑Bevacizumab in Hepatocellular Carcinoma: The Prospective French CHIEF Cohort